Powering Precision Oncology
From Comprehensive Genomic Profiling to Confident Decisions
PanTracer™ Tissue and PanTracer™ LBx
Unlock the complexities of every tumor
PanTracer™ Tissue and PanTracer™ LBx empowers biopharma partners with actionable genomic insights to enable confident, data-driven decisions. From biomarker discovery and target validation to resistance detection, clinical trial enrollment, longitudinal monitoring, and patient stratification – PanTracer™ delivers the molecular clarity needed to advance precision oncology.
Our clinically and analytically validated CGP tests – spanning both tissue and liquid biopsy – work seamlessly to uncover comprehensive molecular insights across pan-solid tumor indications.
PanTracer Tissue LDT
Maximize insights. Minimize tissue. One comprehensive panel
PanTracer tissue streamlines solid tumor profiling by combining DNA and RNA sequencing into a single, comprehensive assay. This approach enables biomarker identification, target validation, and patient stratification, helping to accelerate precision oncology development.
- 517 cancer-relevant genes
- DNA: SNVs, InDels and CNVs – 517 genes
- RNA: Fusions & splice variants – 55 genes
- IO gene signatures - MSI, TMB, HRD*
- High performance DNA + RNA sequencing for optimized fusion detection
| Variant Class | Analytical Sensitivity | Specificity | Accuracy |
|---|---|---|---|
| SNVs | 95.2% | >99.9% | 99.9% |
| InDels | 92.4% | >99.9% | 99.9% |
| CNVs | 100% | 99.6% | 99.7% |
| Fusions | 94.4% | 99.9% | 99.7% |
| LOD | 5% VAF for small variants CNV reporting cutoff is 2.2X fold-change |
*HRD score validated for ovarian cancer only
PanTracer LBx LDT
Simple blood sample. Deep insights. One comprehensive panel
A comprehensive, noninvasive liquid biopsy (ctDNA) lab developed test for solid tumors - enabling biomarker discovery, clinical trial enrollment, and longitudinal monitoring - empowering data-driven decisions even when tumor tissue is limited or unavailable.
- 514 cancer-relevant genes
- SNVs and InDels – 514 genes
- CNVs – 58 genes
- Fusions – 23 genes
- IO gene signatures (MSI-H status; bTMB score)
- High performance ctDNA assay
| Variant Class | Analytical Sensitivity | Specificity | Accuracy | LOD* |
|---|---|---|---|---|
| SNVs/InDels | 92.01% | 99.80% | 99.65% | 0.23% |
| CNVs | 95% | 99.86% | 99.82% | 1.20 fold |
| Fusions | 100% | 100% | 100% | 0.5% |
*LOD90 at 30ng input